Therapeutic vaccination against metastatic carcinoma by expression-modulated and immunomodified autologous tumor cells: a first clinical phase I/II trial.
about
Role of vaccine therapy for renal cell carcinoma in the era of targeted therapyMaintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial.Enhancement of the immune response to residual intrahepatic tumor tissue by laser-induced thermotherapy (LITT) compared to hepatic resection.Human tumor-derived genomic DNA transduced into a recipient cell induces tumor-specific immune responses ex vivo.Immunomodulatory gene therapy for haematological malignancies.Clinical outcomes of active specific immunotherapy in advanced colorectal cancer and suspected minimal residual colorectal cancer: a meta-analysis and system review.Cytokines and antitumor immunity.Granulocyte-macrophage colony stimulating factor: an adjuvant for cancer vaccines.Vaccination immunotherapy--an update.Human cancer gene therapy with cytokine gene-modified cells.Cytokine and vaccine therapy of kidney cancer.A review of evidence-based treatment of stage IIB to stage IV melanoma.Promises and limitations of murine models in the development of anticancer T-cell vaccines.Design and characterization of the tumor vaccine MGN1601, allogeneic fourfold gene-modified vaccine cells combined with a TLR-9 agonist.Overexpression of REIC/Dkk-3 in normal fibroblasts suppresses tumor growth via induction of interleukin-7Evaluation of Pre-Treatment Serum Levels of IL-7 and GM-CSF in Colorectal Cancer Patients.Advances in Non-Viral DNA Vectors for Gene Therapy.Harnessing the biology of IL-7 for therapeutic application.Vaccination therapy in renal cell carcinoma: current position and future options in metastatic and localized disease.Towards effective non-viral gene delivery vector.Comparative antitumor effect of preventive versus therapeutic vaccines employing B16 melanoma cells genetically modified to express GM-CSF and B7.2 in a murine modelExosomes and their Application in Biomedical Field: Difficulties and Advantages.Objective clinical regression of metastatic breast cancer in disparate sites after use of whole-cell vaccine genetically modified to release sargramostim.Safety of intravenous administration of a canarypox virus encoding the human wild-type p53 gene in colorectal cancer patients.Selective expression of tumor necrosis factor-related apoptosis-inducing ligand mediated by microRNA suppresses renal carcinoma growth.Complete tumor prevention by engineered tumor cell vaccines employing nonviral vectors.A convenient cancer vaccine therapy with in vivo transfer of interleukin 12 expression plasmid using gene gun technology after priming with irradiated carcinoma cells.Immunotherapy for renal cell carcinoma
P2860
Q27016032-B60A14AD-2C2C-4AB7-BF61-A0C4FCAAF12FQ30317446-A957493F-9AF1-4014-A0B8-57C2E27813F0Q33208059-495EF36A-370B-49D1-B6EE-B9850C1523C2Q34035529-674AFB4B-1198-42BC-9038-DC095ED6E671Q34579664-79E4D9EB-821B-4E06-95E4-929C69FC282EQ34585684-4744D155-9A58-4C8F-9682-C6995609FC46Q35142319-54E50C28-E8C8-4B0D-BB37-AD89A164C5EAQ35809463-F8FD67B6-0D78-425B-82BD-F293E16D5F53Q35851700-5596DB4E-6D08-4D1A-88EA-05ABED8DF64AQ35907018-B135B8F8-C07F-4562-B903-173B94EB3445Q35987775-0BD9A780-37FA-477E-B12C-A154884CDFA8Q36229746-3DFBD9D7-6B0A-4560-B2C6-7F7315997233Q36684482-D46C12BB-3C35-4D76-ACF6-646D2AAE1627Q36777133-D053C968-01F7-4CE7-A7B7-2E20DE898AFFQ37194209-19E9E52B-E3F2-4219-AC05-0038F827B232Q37590081-DBDB248F-909F-4ADB-A503-6182D000C573Q37676243-C343D113-76E9-446C-9D27-9A58B62AC3A6Q37867487-EB385E53-1D7F-42B6-8B3F-6A883527A117Q37892594-A37E49FD-B71E-4442-8E81-96F5830BEF7FQ38830057-BACE3FA0-E041-4FCC-819A-172AFD40DC1AQ39234383-AC3848FF-E625-4B18-B5F9-8F6AC45A0B69Q39301571-7F2F8C9F-F9EA-45A5-80C0-A6422E771F46Q40234641-1F843DEE-DEE8-4BE9-BAB9-5957B8973787Q40555883-A897018A-118B-40E7-BA1A-193CD7A9A053Q42221018-01C08E7A-DE5A-48DA-9014-FF1033EB8A8CQ45261752-56491BA3-EFE1-49CB-9D6C-CF1AD78F0D26Q45883580-DA685F8B-E7D9-4BBB-8BFC-B50124E2D01CQ58652034-45EAA2A7-A7D0-4949-AA90-7D71BB9E3EA1
P2860
Therapeutic vaccination against metastatic carcinoma by expression-modulated and immunomodified autologous tumor cells: a first clinical phase I/II trial.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Therapeutic vaccination agains ...... rst clinical phase I/II trial.
@ast
Therapeutic vaccination agains ...... rst clinical phase I/II trial.
@en
type
label
Therapeutic vaccination agains ...... rst clinical phase I/II trial.
@ast
Therapeutic vaccination agains ...... rst clinical phase I/II trial.
@en
prefLabel
Therapeutic vaccination agains ...... rst clinical phase I/II trial.
@ast
Therapeutic vaccination agains ...... rst clinical phase I/II trial.
@en
P2093
P1433
P1476
Therapeutic vaccination agains ...... rst clinical phase I/II trial.
@en
P2093
P304
P356
10.1089/10430340150218404
P577
2001-02-01T00:00:00Z